Leishmaniasis Vaccines: Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.Protozoan Vaccines: Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease.Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).Leishmaniasis, Mucocutaneous: A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Antiprotozoal Agents: Substances that are destructive to protozoans.Leishmania: A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi.Leishmania infantum: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). Human infections are confined almost entirely to children. This parasite is commonly seen in dogs, other Canidae, and porcupines with humans considered only an accidental host. Transmission is by Phlebotomus sandflies.Leishmania braziliensis: A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals. It causes cutaneous (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), and mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS) depending on the subspecies of this organism. The sandfly, Lutzomyia, is the vector. The Leishmania braziliensis complex includes the subspecies braziliensis and peruviana. Uta, a form of cutaneous leishmaniasis in the New World, is caused by the subspecies peruviana.Leishmania donovani: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). The sandfly genera Phlebotomus and Lutzomyia are the vectors.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Psychodidae: Small, hairy, moth-like flies which are of considerable public health importance as vectors of certain pathogenic organisms. Important disease-related genera are PHLEBOTOMUS, Lutzomyia, and Sergentomyia.Leishmaniasis, Diffuse Cutaneous: A form of LEISHMANIASIS, CUTANEOUS caused by Leishmania aethiopica in Ethiopia and Kenya, L. pifanoi in Venezuela, L. braziliensis in South America, and L. mexicana in Central America. This disease is characterized by massive dissemination of skin lesions without visceral involvement.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Vaccines, Combined: Two or more vaccines in a single dosage form.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.Phlebotomus: A genus of PSYCHODIDAE which functions as the vector of a number of pathogenic organisms, including LEISHMANIA DONOVANI; LEISHMANIA TROPICA; Bartonella bacilliformis, and the Pappataci fever virus (SANDFLY FEVER NAPLES VIRUS).Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Leishmania tropica: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and rodents. This taxonomic complex includes species which cause a disease called Oriental sore which is a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Leishmania guyanensis: A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals and causes mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS). Transmission is by Lutzomyia sandflies.Leishmania major: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World. Transmission is by Phlebotomus sandflies.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Leishmania mexicana: A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals including rodents. The Leishmania mexicana complex causes both cutaneous (LEISHMANIASIS, CUTANEOUS) and diffuse cutaneous leishmaniasis (LEISHMANIASIS, DIFFUSE CUTANEOUS) and includes the subspecies amazonensis, garnhami, mexicana, pifanoi, and venezuelensis. L. m. mexicana causes chiclero ulcer, a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) in the New World. The sandfly, Lutzomyia, appears to be the vector.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Endemic Diseases: The constant presence of diseases or infectious agents within a given geographic area or population group. It may also refer to the usual prevalence of a given disease with such area or group. It includes holoendemic and hyperendemic diseases. A holoendemic disease is one for which a high prevalent level of infection begins early in life and affects most of the child population, leading to a state of equilibrium such that the adult population shows evidence of the disease much less commonly than do children (malaria in many communities is a holoendemic disease). A hyperendemic disease is one that is constantly present at a high incidence and/or prevalence rate and affects all groups equally. (Last, A Dictionary of Epidemiology, 3d ed, p53, 78, 80)Insect Vectors: Insects that transmit infective organisms from one host to another or from an inanimate reservoir to an animate host.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.DNA, Protozoan: Deoxyribonucleic acid that makes up the genetic material of protozoa.BrazilMeningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Organometallic Compounds: A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.Paromomycin: An oligosaccharide antibiotic produced by various STREPTOMYCES.Mice, Inbred BALB CDNA, Kinetoplast: DNA of kinetoplasts which are specialized MITOCHONDRIA of trypanosomes and related parasitic protozoa within the order KINETOPLASTIDA. Kinetoplast DNA consists of a complex network of numerous catenated rings of two classes; the first being a large number of small DNA duplex rings, called minicircles, approximately 2000 base pairs in length, and the second being several dozen much larger rings, called maxicircles, approximately 37 kb in length.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Parasite Load: Measure of the number of the PARASITES present in a host organism.Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
"Initiative for Vaccine Research (IVR): Parasitic Diseases - Leishmaniasis." Centers for Disease Control and Prevention (1998), ... Department of Communicable Disease Surveillance and Response, WHO; pg 10. David Bernstein, M.D., "Intestinal Parasite ... World Health Organization, (2013) "Health Topics: Leishmaniasis." Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke ...
Her research covers the development of diagnostic tests and attenuated vaccines, drug resistance and immune responses for ... and the study of drug resistance and immune responses in patients suffering from Leishmaniasis, a disease spread by the bite of ... and Cutaneous Leishmaniasis. "POONAM SALOTRA, SCIENTIST G & DIRECTOR INCHARGE". "Biodata Poonam Salotra" (PDF). "Leishmaniasis ... She has published more than 95 academic papers and holds 2 US patents, both related to Leishmaniasis. She has 18 years of ...
As of 2017, no leishmaniasis vaccine for humans was available.[54][55] Research to produce a human vaccine is ongoing.[56] ... and Leishmania has unique features with respect to the regulation of gene expression in response to changes in the environment ... Cutaneous leishmaniasis in the hand of a Central American adult. Pronunciation. *Leishmaniasis /ˌliːʃməˈnaɪəsɪs/. leishmaniosis ... Currently some effective leishmaniasis vaccines for dogs exist.[57] There is also consideration that public health practices ...
"Status of vaccine research and development of vaccines for leishmaniasis". Vaccine. 34 (26): 2992-2995. doi:10.1016/j.vaccine. ... 2005). "Immune Response in Human Visceral Leishmaniasis: Analysis of the Correlation between Innate Immunity Cytokine Profile ... As of 2018, there are no vaccines or preventive drugs for visceral leishmaniasis, but vaccines are in development.[33][34] The ... Visceral leishmaniasis (VL), also known as kala-azar[2] (UK: /ˌkɑːlə əˈzɑːr/), is the most severe form of leishmaniasis and, ...
Malaria vaccine research and drug resistant falciparum malaria epidemiology Investigation of Multi-drug resistant Nosocomial ... Surveillance of avian influenza-NAMRU-3 is active in the global response to the threat of avian and pandemic influenza. ... Ethiopia and in the early 1970s a similar detachment in the Sudan focusing on malaria and leishmaniasis research. The Ethiopian ... The modern mission of the NAMRUs is threefold: To investigate prophylactic agents such as vaccines and pharmaceuticals against ...
Since many antigens derived from acellular vaccines do not strongly induce the adaptive response, most bacterial vaccines are ... and leishmaniasis (Leishmania spp.). Other bacteria, such as Mycobacterium tuberculosis, live inside a protective capsule that ... Most viral vaccines are based on live attenuated viruses, while many bacterial vaccines are based on acellular components of ... B cells are involved in the humoral immune response, whereas T cells are involved in cell-mediated immune response. Both B ...
When used with systemic antibiotics such as paromomycin, the cholera vaccine can cause an immune response. Use with strong ... and other diseases such as leishmaniasis. Paromomycin was demonstrated to be effective against cutaneous leishmaniasis in ... Paromomycin is an antibiotic used to treat a number of infections including amebiasis, giardiasis, leishmaniasis, and tapeworm ... 2013). "Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis". N. Engl. J. Med. 368 (6): 524-32. doi: ...
Implementation of NAMRU-6's mission is via threefold means: to investigate prophylactic agents such as vaccines and ... NAMRU-6 is active in the global response to the threat of avian and pandemic influenza including an outbreak of H1N1 on ... demonstrating superiority of glucantime to pentamidine therapy for cutaneous leishmaniasis in 2005, developing non-human ... Important scientific achievements include completing a Cholera vaccine field efficacy trial on 18,000 volunteers in Peru in ...
If an effective vaccine is developed in the coming years, Western governments and pharmaceutical companies will come under ... Development of an integrated global surveillance and response system probably is at least a decade or more away. This owes to ... Other recent disease concerns include meningococcal Meningitis outbreaks in the Benelux countries and leishmaniasis-HIV co- ... dead link] "Response Capacity", National Intelligence Estimate 99-17D: The Global Infectious Disease Threat and Its ...
Leishmaniasis and Lymes disease. Given that there is currently no approved Lyme vaccine for humans, but there is for dogs, ... These T-cells can be engineered to be resistant to anti-cancer drugs and to invoke immune responses against targets of interest ... Kevin Esvelt, an associate professor of biological engineering at MIT has proposed using the vaccine on white-footed mice. If ... could lead to the manufacture of biological weapons by potential bioterrorists who might use the knowledge to create vaccine ...
"Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil". Vaccine. 25 (12): 2180-6. doi: ... 2005) Characterization of Canine Leishmaniasis in the United States: Pathogenesis, Immunological Responses, and Transmission of ... "Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine". Vaccine. 25 (33 ... September 2005). "Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites ...
Aeras Global TB Vaccine Foundation: The foundation gave the Aeras Global TB Vaccine Foundation more than $280 million to ... In response, the Gates Foundation has said that African governments need to spend more of their budgets on public health than ... Visceral leishmaniasis (VL) research: The foundation awarded the Hebrew University of Jerusalem's Kuvin Center for the Study of ... Children's Vaccine Program: The Children's Vaccine Program, run by the Program for Appropriate Technology in Health (PATH), ...
They run three main programs, Sabin Vaccine Development, Global Network for Neglected Tropical Diseases, and Vaccine Advocacy ... In response to a growing awareness to the burden on these populations, the European Centre for Disease Prevention and Control ... Leishmaniasis can be treated with expensive medications. There were 189,018 known cases of leprosy in March 2013, and 232,857 ... The BCG vaccine has some preventative effect against leprosy. Leprosy has a 5-20 year incubation period, and the symptoms are ...
Malaria vaccines are an area of intensive research. Intestinal parasites are extremely prevalent in tropical areas. These ... These parasitic diseases, affect the body's immune response to HIV, making people more susceptible to contracting the disease ... Chagas disease and Leishmaniasis. Africa accounts for a majority of malaria infections and deaths worldwide. Over 80 percent of ... Borkow G, Bentwich Z (May 2002). "Host background immunity and human immunodeficiency virus protective vaccines, a major ...
Holaday BJ (1999). "Immunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of ... Human Vaccines & Immunotherapeutics. 8 (10): 1459-1464. doi:10.4161/hv.21405. ISSN 2164-5515. PMID 23095864. Cousens, Leslie P ... T regulatory cells are a component of the immune system that suppress immune responses of other cells. This is an important " ... Most tumors elicit an immune response in the host that is mediated by tumor antigens, thus distinguishing the tumor from other ...
Vaccines. Main article: Ebola vaccine. Many Ebola vaccine candidates had been developed in the decade prior to 2014,[102] but ... "Ebola Response Roadmap Situation Report" (PDF). World Health Organization. 1 October 2014. Archived (PDF) from the original on ... visceral leishmaniasis, measles, and viral hepatitis among others.[98] ... prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease.[106][107][7] More than 100,000 people ...
... developed a simple non-radioactive methodology for the study of DNA impressions and the American visceral leishmaniasis vaccine ... and neuroendocrinologic response to exercise. In the Department of Physiotherapy and Occupational Therapy, there are projects ... ICB topics of research responsible for the largest number of publications are those related to the development of new vaccines ...
Mammalian hosts react to infections with an innate response, often involving inflammation, followed by an adaptive response. ... Vaccine Research Center Information concerning vaccine research clinical trials for Emerging and re-Emerging Infectious ... leishmaniasis, onchocerciasis, schistosomiasis and trypanosomiasis. "WHO , The top 10 causes of death". WHO. Retrieved 2015-09- ... The immune system response to a microorganism often causes symptoms such as a high fever and inflammation, and has the ...
There are no vaccines or preventive drugs for visceral leishmaniasis. The most effective method to prevent infection is to ... Because visceral leishmaniasis patients lack these responses to leishmania and other antigens, they usually die of secondary ... Thus, the CD8+ T regulatory cells reproduce the immune response characteristic of visceral leishmaniasis. CD8+ T regulatory ... Visceral leishmaniasis (VL), also known as kala-azar, black fever, and Dumdum fever, is the most severe form of leishmaniasis ...
T. gondii achieves this balance by manipulating the host's immune response, reducing the host's immune response and enhancing ... It is difficult to control the cat population with the infected oocysts due to lack of an effective vaccine. This remains a ... Klaus, Sidney N.; Shoshana Frankenburg, and A. Damian Dhar (2003). "Chapter 235: Leishmaniasis and Other Protozoan Infections ... on the immune response to other pathogenic threats. This includes, but is not limited to, the responses to infections by ...
Vaccines. Main article: Ebola vaccine. An Ebola vaccine, rVSV-ZEBOV, was approved in the United States in December 2019.[8] It ... Videos: Ebola outbreak response - World Health Organization. *. "Ebola Preparedness and Response". U.S. Food and Drug ... visceral leishmaniasis, measles, and viral hepatitis among others.[104] ... "Ebola Response Roadmap Situation Report" (PDF). World Health Organization (WHO). 1 October 2014. Archived (PDF) from the ...
Journal of Biopesticides, 5: 1-11.[7] Ashworth, J.R. & Wall, R. (1994) Responses of the sheep blowflies Lucilia sericata and L. ... 2009) Cutaneous leishmaniasis caused by Leishmania infantum transmitted by Phlebotomus tobbi. International Journal for ... There are commercially available vaccines to protect animals against bluetongue, and African horse sickness Myiasis: Centers ... sandflies are notorious as transmitters of species of Leishmania protozoa that cause visceral and cutaneous leishmaniasis in ...
In response to an EDF suit, the U.S. District Court of Appeals in 1971 ordered the EPA to begin the de-registration procedure ... In 2009, 3,314 tonnes were produced for malaria control and visceral leishmaniasis. India is the only country still ... a hypothetical vaccine and changing front-line drug treatment, found decision making limited by the lack of information on the ... As its production and use increased, public response was mixed. At the same time that DDT was hailed as part of the "world of ...
The response to the epidemic then moved to a second phase, as the focus shifted from slowing transmission to ending the ... Many Ebola vaccine candidates had been developed in the decade prior to 2014, but as of November 2014, none had been approved ... visceral leishmaniasis, measles, and viral hepatitis among others. Non-infectious diseases that may result in symptoms similar ... "Ebola Response Roadmap Situation Report" (PDF). World Health Organization. 1 October 2014. Archived (PDF) from the original on ...
Mammalian hosts react to infections with an innate response, often involving inflammation, followed by an adaptive response.[3] ... Vaccine Research Center Information concerning vaccine research clinical trials for Emerging and re-Emerging Infectious ... Tropical diseases include Chagas disease, dengue fever, lymphatic filariasis, leishmaniasis, onchocerciasis, schistosomiasis ... The immune system response to a microorganism often causes symptoms such as a high fever and inflammation, and has the ...
Use in vaccinesEdit. The first vaccine against smallpox by Edward Jenner in 1800 was by infection of a zoonotic bovine virus ... Leishmaniasis Leishmania spp. dogs, rodents, other animals[32][33]. sandfly bite Leprosy Mycobacterium leprae, Mycobacterium ... expansion of epidemics depend on frequent contact with other individuals who have not yet developed an adequate immune response ... "Parasites - Leishmaniasis". CDC. 27 February 2019. Archived from the original on 15 June 2019. Retrieved 19 June 2019.. ...
I will divide the studies we have done to develop a vaccine to prevent and treat cutaneous leishmaniasis into two stages. Both ... response, curable by immunotherapy or chemotherapy; DCL, T helper type 2 (Th2) response, characterized by an antigen-specific ... However, in an WHO evaluation of the results from the immunotherapy trials with this vaccine in areas endemic for leishmaniasis ... Since 1981 I have published 105 scientific papers, mainly on leprosy and leishmaniasis vaccines and control. I have also ...
... depending mainly on hosts immune response. Mucosal leishmaniasis is an atypical presentation form produced by metastatic ... Mucosal Leishmaniasis: An Atypical Form of Canine Leishmaniasis (Prospective Screening Carried Out Over 983 Dogs) ... Canine leishmaniasis is an endemic zoonotic disease highly widespread in the Mediterranean basin. There is a broad spectrum on ... To try to describe five new cases of mucosal leishmaniasis is the first objective of this work, one of the cases was localized ...
... is required to control leishmaniases. Therefore, simple tests that can evaluate the cellular immunity of the target populations ... Leishmania infantum is the causative agent of visceral leishmaniasis (VL). Cell-mediated immunity (CMI) ... Keywords: Visceral leishmaniasis, Leishmania infantum, skin test, Leishmanin, delayed-type hypersensitivity (DTH) test, ... Introduction: Leishmania infantum is the causative agent of visceral leishmaniasis (VL). Cell-mediated immunity (CMI) is ...
Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis. Maria L. B. Sousa-Atta, Gregório S. Salamé, ... Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis. Maria L. B. Sousa-Atta, Gregório S. Salamé, ... Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis. Maria L. B. Sousa-Atta, Gregório S. Salamé, ... Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J. Infect. Dis. 180:1731-1734. ...
We evaluated cytokine responses against 6 defined candidate vaccine antigens in 15 cured VL subjects and 5 healthy endemic ... Among candidate vaccine antigens tested, the largest number of cured subjects recognized cysteine proteinase B, leading to ... Further studies may help prioritize antigens for clinical development of a subunit vaccine against VL. ... indicating a relationship between T cell recall responses of humans cured from VL and protective efficacy in an experimental ...
However, with antigens from L. chagasi (a causative agent of American visceral leishmaniasis), there was no significant ... The proliferative responses of peripheral blood mononuclear cells (PBMC) induced by antigens from dermotropic Leishmania ... braziliensis antigens in proliferative response assays. In all cases, the majority of the responding cells were CD8+ T cells, ... in contrast to the results of a group of patients with active lesions of tegumentary leishmaniasis, whose L. braziliensis- ...
Vaccine. 2007 Aug 29;25(35):6544-56. Epub 2007 Jun 8. Research Support, Non-U.S. Govt ... neutral and positively charged liposomes with the elicited immune responses to predict vaccine success in experimental VL. ... An ideal vaccine should be effective in both preventing and treating leishmaniasis. However, immunological correlates to ... The best vaccine formulation, SLA in positively charged liposomes, was then used for immunotherapy. This vaccine induced more ...
The complete understanding of these issues will be essential for the approval of a successful vaccine for human leishmaniasis. ... although it is widely accepted that a prophylactic vaccine for human leishmaniasis is the way to achieve the successful ... However, and in spite of the different candidates tested along the years, till date, we still do not have an approved vaccine ... In this chapter, we will explore the last advances made in the field of vaccines against Leishmania without forgetting the ...
... vaccine biology; inhibitors of Leishmania DNA topoisomerases; and mechanism of drug resistance in visceral Leishmaniasis. An ... oxidative and nitrosative stress response; cell death; strategies for immune evasion; STAT signalling; parasite modulation of ...
Development of a leishmaniasis vaccine: the importance of Mpl. Expert Review of Vaccines 2: 239-252. *PubMed , ... Garg R & Dube A (2006) Animal models for vaccine studies for visceral Leishmaniasis. Int J Med Res 123: 439-454. *PubMed , ... Campos-Neto A (2005) What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Braz J Med Biol Res 38: 979-984. * ... Reed SG & Scott P (1993) T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5: 524-531. *CrossRef , ...
The T helper cell type 1 (Th1) response is essential to resist leishmaniasis, whereas the Th2 response favors the disease. ... Development of a leishmaniasis vaccine: the importance of Mpl. Expert Review of Vaccines, 2: 239-252. [ Links ]. 36. Stobie L, ... However, they by no means challenge the concept that a Th1 response is essential for protection against leishmaniasis. Indeed, ... the Th1 response that is elicited during infection can be an efficient alternative in vaccine development against leishmaniasis ...
From Genomes to Vaccines for leishmaniasis. Erik Rollman, BioArctic, Sweden HPV-16 L1 Genes with Inactivated Negative RNA ... Engineering Improved DNA Vaccine Immune Responses. * Nicholas P. Restifo, NCI, National Institutes of Health, USA How ... Dominance in T Cell Responses to Smallpox Vaccination. Søren Buus, University of Copenhagen, Denmark SARS CTL Vaccine ... Induction of T-Cell Immunity by a Plant Virus Vaccine. Martin Friede, World Health Organization, Switzerland Vaccines and ...
Finally, we determined if IFN-gamma might augment vaccine induced immunity. We found that s.c. immunization with soluble ... IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.. P Scott ... IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. ... IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. ...
... vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs . Opens in a new ... deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response ... A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing *Wen ... Rights & permissionsfor article A second generation leishmanization vaccine with a markerless attenuated ,i,Leishmania major,/i ...
... vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs . Opens in a new ... deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response ...
"A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to ... S. Bertholet, Y. Goto, L. Carter et al., "Optimized subunit vaccine protects against experimental leishmaniasis," Vaccine, vol ... MPL-SE vaccine for use in the prevention of visceral leishmaniasis," Vaccine, vol. 29, no. 19, pp. 3531-3537, 2011. View at ... "First generation leishmaniasis vaccines: a review of field efficacy trials," Vaccine, vol. 26, no. 52, pp. 6759-6767, 2008. ...
Section III: Genetic Determinants of Infectious Diseases and Response to Vaccines. 18. Immune Deficiency Disorders. 19. Human ... Section II: Immune Response Genes and Infection. 4. MHC Class I and Related Genes. 5. MHC Class II and Related Genes. 6. MHC ...
Tolerability And Immune Response Following Vaccination With Immunose™ FLU In Older Adults PubMed Journal Articles published on ... Recombinant cysteine peptidase vaccine can induce protective immunity against cutaneous leishmaniasis. However, the antigenic ... Immune Response in Highly Active Young Men to the 2014/15 Seasonal Influenza Vaccine. ... High immune response (HIR) cows have a balanced and robust host defense and lower disease incidence, and immune response is ...
... immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg 53: 195-201. [ Links ]. ... American cutaneous leishmaniasis: in situ characterization of the cellular immune response with time. Am J Trop Med Hyg 50: 743 ... Immune response in leishmaniasis is implicated in both protection and immunopathology. The predominant IFN-g and B cell ... Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania ...
... deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response ... Vaccine development. *. Vaccines against visceral leishmaniasis are in different stages of development323334 Financial support ... Vaccine development: leishmaniasis. www.who.int/tdr/research/progress/9900/vaccine_dev_leish/en. ... Mukhopadhyay A, Syamal R, Gupta D, Guha R, Rastogi R. Hemoglobin receptor as novel vaccine for leishmaniasis. WO patent ...
IL2RA Genetic Variants Reduce IL-2-Dependent Responses and Aggravate Human Cutaneous Leishmaniasis Pablo R. S. Oliveira, Hélia ... IMMUNOTHERAPY AND VACCINES. *. Open Access. Hydroxypropyl-β-Cyclodextrin Spikes Local Inflammation That Induces Th2 Cell and T ... INFECTIOUS DISEASE AND HOST RESPONSE. *. You have accessRestricted access. Filarial Infection Modulates the Immune Response to ... Functional Heterogeneity in the CD4+ T Cell Response to Murine γ-Herpesvirus 68 Zhuting Hu, Marcia A. Blackman, Kenneth M. Kaye ...
... research using animal models of experimental visceral or cutaneous leishmaniasis has allowed to dissect the immune response to ... To date, a vaccine is lacking and strategies to treat severe forms of leishmaniasis efficiently are missing.Basic ... This research topic aims to cover a broad range of important concepts in adaptive and innate immunity to leishmaniasis and will ... We welcome both reviews and original research articles that cover the latest breakthroughs in leishmaniasis research. We ...
What is American leishmaniasis? Meaning of American leishmaniasis medical term. What does American leishmaniasis mean? ... Looking for online definition of American leishmaniasis in the Medical Dictionary? American leishmaniasis explanation free. ... There is no vaccine against Leishmania. To prevent infection during exposure to sandfly vectors, topical repellants containing ... Leishmania organisms infect and reproduce inside macrophages and are controlled by T-cell-mediated response. The strength of ...
Immunoglobulin E Antileishmanial Antibody Response in Cutaneous Leishmaniasis Maria L. B. Sousa-Atta, Gregório S. Salamé, ... Immune-Mediated Responses and Disorders. *. IMMUNE-MEDIATED RESPONSES AND DISORDERS. Development of Internal Controls for the ... Host Cell Responses to Genotypically Similar Helicobacter pylori Isolates from United States and Japan Takafumi Ando, Richard M ... IMMUNE-MEDIATED RESPONSES AND DISORDERS. Serum S100B Levels in Patients with Lupus Erythematosus: Preliminary Observation Luis ...
Leishmaniasis is a severe infectious disease. Drugs used for leishmaniasis are very toxic, and no vaccine is available. We ... HbR-DNA vaccination also induced a protective response by generating multifunctional CD4+ and CD8+ T cells. All HbR-DNA- ... These findings demonstrate the potential of HbR as a vaccine candidate against visceral leishmaniasis. ... Research ArticleLeishmaniasis. Vaccination with Leishmania Hemoglobin Receptor-Encoding DNA Protects Against Visceral ...
  • Antileishmanial immunity is mediated by both innate and adaptive immune responses and requires effective activation of macrophages, dendritic cells (DCs), and antigen-specific CD4 + and CD8 + T cells [ 4 ]. (hindawi.com)
  • These particles are involved in intercellular communication, modulating a wide range of signaling events during innate and acquired immune responses (Figure 1 and Table 1 ) [ 2 - 4 ]. (hindawi.com)
  • The Idoyaga Lab is focused on the function and biology of dendritic cells, which are specialized antigen-presenting cells that initiate and modulate our body?s immune responses. (stanford.edu)
  • Considering their importance in orchestrating the quality and quantity of immune responses, dendritic cells are an indisputable target for vaccines and therapies. (stanford.edu)
  • Our research program focuses on advancing our understanding of mouse and human dendritic cell subsets, revealing their endowed capacity to induce distinct types of immune responses, and designing novel strategies to exploit them for vaccines and therapies. (stanford.edu)
  • Her research covers the development of diagnostic tests and attenuated vaccines, drug resistance and immune responses for patients suffering from Leishmaniasis in some form. (wikipedia.org)
  • Her research especially covers the development of diagnostic tests and attenuated vaccines, and the study of drug resistance and immune responses in patients suffering from Leishmaniasis, a disease spread by the bite of certain types of sandflies that kills between 20 000 - 50 000 people each year. (wikipedia.org)
  • Accumulating evidence suggests that acute stressors (those lasting minutes to hours) can augment immune responses. (springer.com)
  • In contrast, chronic stressors (those lasting weeks to years) are associated with dysregulation of the HPA axis, impaired innate and adaptive immune responses, and adverse health outcomes. (springer.com)
  • View Department of Pathology profile » My main research interest is to better understand the mechanisms that enable emerging viruses to evade host immune responses and cause disease, and to identify cellular factors that contribute to viral infection. (utmb.edu)
  • We then compared the immune responses in C57BL/6 mice following infection with WT or Δ lpg2 mutant parasites. (asm.org)
  • Viruses carried within mosquito saliva may more easily initiate host infection by taking advantage of the host's innate and adaptive immune responses to saliva. (deepdyve.com)
  • Using mouse and cell culture infection models, she examines how innate and adaptive immune responses against bacteria, viruses, and parasites are regulated, which host‐ and pathogen‐derived factors are responsible for disease pathogenesis, and which molecules can be incorporated into the disease control regimen. (utmb.edu)
  • In Dr. Bruce Freedman's laboratory the main focus is signaling pathways that regulate lymphocyte and macrophage development and function, work that has ramifications in understanding immune responses to both infections and tumors. (upenn.edu)
  • MAIN CONCLUSIONS: Our results showed that L. braziliensis and L. infantum induce different innate immune responses and a highly inflammatory profile, which is characteristic of infection by L. infantum, the species associated with visceral disease. (bvsalud.org)
  • In both BALB/c (Th2-biased) and B10.D2 (Th1-biased) mice, immunization with HEL in incomplete Freund's adjuvant (IFA) resulted in Th2-dominated immune responses characterized by HEL-specific secretion of IL-5 but not IFN-γ. (rupress.org)
  • We have investigated the development of the typical granulomatous lesions in the liver in experimental VL over time, together with the local immune responses. (biomedcentral.com)
  • Additionally, we can investigate the immune responses of other infections which could lead to better vaccines. (infectioncontroltoday.com)
  • Synthetic CpG-oligodeoxynucleotides (CpG-ODN) are potent adjuvants that accelerate and boost antigen-specific immune responses. (usda.gov)
  • Of the 6 cytokines examined, only interferon-gamma (IFN-γ) differentiated cured VL patients from non-exposed individuals, with cured patients mounting a significantly higher IFN-γ response to a crude parasite antigen preparation. (ajtmh.org)
  • The CD4 + subset of T cells is crucial for resistance, whereas CD8 + T cells seem to participate more in the memory events of the immune response than as effector cells involved in parasite elimination. (scielo.br)
  • There are some 10+ million people currently infected with the parasite worldwide, and leishmaniasis threatens 350 million people in 88 countries. (idri.org)
  • Current treatment for leishmaniasis is based on chemotherapy, which relies on a handful of drugs that are associated with serious limitations such as high cost, toxicity and lack of efficacy in endemic areas where the parasite is transmitted. (idri.org)
  • Moreover, the complex compound acts as a therapeutic vaccine which activates the immune system against the reservoir cells hosting the parasite. (medindia.net)
  • Furthermore, a dendritic cell-based vaccination against leishmaniasis efficiently suppresses the early secretion of IL-10, thus contributing to the control of parasite spread. (uni-wuerzburg.de)
  • With more than 12 million people affected worldwide, 2 million new cases occurring per year, and the rapid emergence of drug resistance and treatment failure, leishmaniasis is an infectious disease for which research on drug and vaccine development, host-pathogen, and vector-parasite interactions are current international priorities. (sciencemag.org)
  • The outbreak regions closest to the United States of leishmaniasis, the disease caused by the parasite , have come within roughly 300 miles of the border. (gatech.edu)
  • If another form of the parasite gets into the bloodstream, it can damage the liver and spleen in a deadly form of the disease called visceral leishmaniasis, also known as black fever. (gatech.edu)
  • Haemoculture as a tool for diagnosing visceral leishmaniasis in HIV-negative and HIV-positive patients: interest for parasite identification. (who.int)
  • A secreted parasite antigen-based vaccine has recently been licensed for use in dogs in Brazil. (gopetsamerica.com)
  • And the parasite starts to amplify them extensively as small circular molecules in response to a stress. (youris.com)
  • At several meetings, we have recommended setting up a deep surveillance of the parasite and its response to drugs. (youris.com)
  • By contrast, BALB/c mice develop a typical Th2 response. (scielo.br)
  • BALB/c mice are extremely susceptible to L. major in part due to the development of a Th2 response ( 8 ). (asm.org)
  • Since T cells and professional APC are important cellular sources of IL-10, we compared leishmaniasis disease progression in T cell-specific, macrophage/neutrophil-specific and complete IL-10-deficient C57BL/6 as well as T cell-specific and complete IL-10-deficient BALB/c mice. (uni-wuerzburg.de)
  • In this study, since vacuolar (H+)-ATPase (V-ATPase) enzyme has an essential role in the life cycle of eukaryotes, V-ATPase subunit F gene has been chosen to design DNA vaccine and evaluate its immunogenicity in BALB\c mice. (magiran.com)
  • BALB/c mice were immunized subcutaneously three times at an interval of two weeks with designed vaccine. (magiran.com)
  • Unlike the case with VL, patients with CL have a strong Th1 immune response, evidenced by a positive type IV hypersensitivity skin reaction and high IFN-γ production by peripheral blood mononuclear cells stimulated ex vivo by leishmanial antigens ( 6 , 9 ). (asm.org)
  • Among candidate vaccine antigens tested, the largest number of cured subjects recognized cysteine proteinase B, leading to heightened IFN-γ responses, followed by sterol 24-c-methyltransferase. (ajtmh.org)
  • These two antigens were the most immunogenic and protective antigens in a murine VL model, indicating a relationship between T cell recall responses of humans cured from VL and protective efficacy in an experimental model. (ajtmh.org)
  • However, many leishmanial antigens, which stimulate a Th1 immune response during the disease or even after the disease is cured, have been shown to have no protective action. (scielo.br)
  • By using T cells from the blood of individuals who had been cured of Leishmaniasis, they made sure these antigens also elicited a T-cell-mediated immune response in humans. (natureasia.com)
  • The DNA vaccine developed from these antigens protected mice when they were injected with it. (natureasia.com)
  • Whole microbes, microbial subunits and extracts, and peptide and protein antigens have been the focus of much vaccine research and development. (cdc.gov)
  • The goals of this workshop were to examine the mechanisms involved in generating an appropriate immune response to selected carbohydrate antigens, highlight recent and novel advances, and discuss how this information could be used in the development of effective vaccines. (cdc.gov)
  • Understanding the mechanistic aspects of the genetic control and the cellular pathways of the immune response to bacterial carbohydrate antigens should provide insights into ways to enhance the immune response and thus facilitate vaccine development. (cdc.gov)
  • The design of optimal vaccines against such pathogens should include lipid and peptide antigens. (cdc.gov)
  • View Department of Microbiology & Immunology profile » My research focuses on tick-borne hemorrhagic fever viruses, including their pathogenesis, ecology, tick-virus interaction, and vaccine development. (utmb.edu)
  • http://www.who.int/mediacentre/factsheets/fs100/en/ Centers for Disease Control and Prevention, (16 August 2010) "Eastern Equine Encephalitis. (wikipedia.org)
  • A mixture of safe Leishmaniafar .ha:sandan adjuvant that preferentially stimulates cellular immune response presentsanug.e I option for a vacci.n' e against Ie' ishmam.asi.s, A vaccm. (ac.ke)
  • The type of Th response generated to an administered antigen can be directed by the type of adjuvant used. (rupress.org)
  • This form of leishmaniasis, mucosal leishmaniasis (ML), might not be noticed until years after the original skin sores appear to have healed. (cdc.gov)
  • A third form, Mucosal Leishmaniasis, compromises the nasal, oral and pharyngeal mucosa, leading to death by suffocation or starvation in the worst cases. (osu.edu)
  • INTRODUCTION: As highly specific molecular biology-based techniques may not be sensitive enough for the diagnosis of American tegumentary leishmaniasis (ATL), clinicians frequently rely on immunological tests before treatment initiation. (bvsalud.org)
  • Given that group B meningococcal capsular polysaccharide is similar to host molecules, studies are ongoing to identify vaccine candidates that elicit protective antibody without eliciting autoantibodies. (cdc.gov)
  • With IDRI's longstanding contribution recognized by abundant mentions of our development of tools such the rK39 rapid diagnostic test and adjuvants to support vaccine development programs, the conference also provided opportunity to meet and expand our wide ranging collaborative network. (idri.org)
  • In an effort to develop anti-leishmaniasis vaccines and adjuvants, novel carbohydrate-based probes were made to study the mechanisms of immune modulation. (beilstein-journals.org)
  • This study used the vervet monkey model of visceral leishmaniasis to:valuatethe safety, immunogenicity and efficacy of Leishmaniadonovanisonicateantigen(Ag) delivered alone or in conjunction with alum-BCG (AIBCG), monophosphoryl lipidA (MPL) or montanideISA 720 (MISA) as adjuvants. (ac.ke)
  • The recent discovery that certain DNA preparations affect cytokine expression by cells of the innate immune system suggests the possibility that DNA preparations could be used as adjuvants to influence the differentiation of Th responses. (rupress.org)
  • A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed. (sanger.ac.uk)
  • Spilki F, Esteves P, da Silva A, Franco A, Rijsewijk F, Roehe P. A monoclonal antibody-based ELISA allows discrimination between responses induced by bovine herpesvirus subtypes 1 (BoHV-1.1) and 2 (BoHV-1.2). (labome.org)
  • High antibody responses against rLiPUF1 and rLiPUF2 were found in sera from VL patients, but these proteins resulted also recognized by sera from Chagas' disease patients. (csic.es)
  • Thus the treatment and control of PKDL are an important public health measure for controlling VL and must be considered in the development of VL vaccine strategies. (hindawi.com)
  • Therefore, mechanisms involved in wound healing, chronic inflammation, host pathogen interactions and the development of long lasting memory responses can be interrogated. (frontiersin.org)
  • Baylor currently serves as President and CEO of Biologics Consulting, a regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices based in Alexandria, VA. He joined Biologics Consulting after 20 years with the FDA, most recently as the director of the Office of Vaccines Research and Review. (idri.org)
  • During his tenure at the FDA, Baylor evaluated and facilitated the development and licensure of numerous new vaccines, such as acellular pertussis, varicella, pneumococcal conjugate, human papillomavirus (HPV) influenza, zoster and all of the new-generation combination vaccines. (idri.org)
  • The development of vaccines is the essential aim of studies of leishmaniasis. (asm.org)
  • While much has been learned about the development of Th1 cells, our understanding of how to maintain Th1 responses is limited. (upenn.edu)
  • However, our understanding of several aspects of polysaccharide vaccines is limited, and more knowledge is needed to allow greater development and deployment. (cdc.gov)
  • Presentations from several invited experts emphasized the current challenges facing the development of vaccines for meningococcal meningitis. (cdc.gov)
  • View Department of Pathology profile » Our laboratory is undertaking development of flavivirus vaccines, including West Nile, Japanese encephalitis, Zika, yellow fever and dengue. (utmb.edu)
  • We aim to facilitate development of new and improved vaccines, diagnostics and therapeutics for this important group of emerging and re-emerging arthropod-borne viruses. (utmb.edu)
  • To effectively exploit nanotechnology in vaccine development, we must first consider the possible mechanisms which support effective immunisation. (springer.com)
  • There are no licensed vaccines against most of these viruses, and vaccine development and use has been complicated by the number of different viruses to protect against, by subtype and strain variation, and by the inability to predict when and where outbreaks will occur. (deepdyve.com)
  • A DENV vaccine is now licensed in select countries, but its development has been more complicated given the presence of 4 circulating serotypes and controversies surrounding the phenomenon of possible vaccine-induced immune potentiation of more severe illness in children [2, (deepdyve.com)
  • Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. (semanticscholar.org)
  • The laboratory has defined target vaccine candidate molecules and is collaborating with the University of Iowa and Cambridge University in a project directed toward the development of a multi-subunit vaccine. (yale.edu)
  • In addition, we have collaborated with Dr. Tarek Fahmy (Yale Bioengineering) in the development of nanoparticle therapeutic treatment delivery system for leishmaniasis. (yale.edu)
  • Co-Organizer, International Conference on post-genomic research strategies for the development of vaccines and drugs against leishmaniasis. (yale.edu)
  • Understanding the basic mechanisms that shape the immune response to tumors has direct implications for the development of new therapies for cancer. (upenn.edu)
  • Dr.Nicola Mason's laboratory focuses on the bench to bedside development of novel immunotherapeutic strategies to augment cytotoxic T cell responses against common cancers in domestic dogs. (upenn.edu)